Skip to main content
. Author manuscript; available in PMC: 2012 Dec 20.
Published in final edited form as: J Neurosci. 2012 Jun 20;32(25):8532–8544. doi: 10.1523/JNEUROSCI.0337-12.2012

Figure 8. M1 agonists VU0357017 and VU0364572 enhance performance in Morris water maze and contextual fear conditioning in rats.

Figure 8

(a.) Swim distance across the 5 days of testing in the water maze. Data are collapsed across 4 daily trials and across groups of VU0364572 or vehicle treated animals. (b.) Effects of treatment with VU0364572 on spatial memory on days 4 and 5 of testing in Morris water maze assays. (c.) Effects of treatment with VU0364572 on memory retention between Day 4 Trial 4 and Day 5 Trial 1 (n=8). + P<0.05 vs. Day 4 for vehicle-treated animals only. * P ≤ 0.02 vs. vehicle treated animals for Day 5 (n=8). (d.) Effects of treatment with VU0364572 on platform crossings during the first 30 sec of the probe trial. (e.) Swim distance across the 5 days of testing in the water maze. Data are collapsed across 4 daily trials and across groups of VU0357017 or vehicle treated animals. (f.) Effects of treatment with VU0357017 on spatial memory on days 4 and 5 of testing (n=8). (g.) Effects of treatment with VU357017 on spatial memory retention between Day 4 Trial 4 and Day 5 Trial 1 (n=8). (h.) Effects of treatment with VU0357017 on platform crossings during the first 30 sec of the probe trial. (i.) Effects of treatment of VU0364572 on acquisition of contextual fear in rats (n=4–6, each group). (j.) Effects of VU0357017 treatment on acquisition of contextual fear in rats (n=4–6, each group).